These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 35275542)

  • 1. Neurofilament Light Chain Levels in Frontotemporal Dementia and Progressive Supranuclear Palsy: A Systematic Review.
    Bendstrup N; Hejl AM; Salvesen L
    J Alzheimers Dis; 2022; 87(1):131-140. PubMed ID: 35275542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical value of neurofilament and phospho-tau/tau ratio in the frontotemporal dementia spectrum.
    Meeter LHH; Vijverberg EG; Del Campo M; Rozemuller AJM; Donker Kaat L; de Jong FJ; van der Flier WM; Teunissen CE; van Swieten JC; Pijnenburg YAL
    Neurology; 2018 Apr; 90(14):e1231-e1239. PubMed ID: 29514947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal Fluid Biomarkers in Patients with Frontotemporal Dementia Spectrum: A Single-Center Study.
    Abu-Rumeileh S; Mometto N; Bartoletti-Stella A; Polischi B; Oppi F; Poda R; Stanzani-Maserati M; Cortelli P; Liguori R; Capellari S; Parchi P
    J Alzheimers Dis; 2018; 66(2):551-563. PubMed ID: 30320576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders.
    Olsson B; Portelius E; Cullen NC; Sandelius Å; Zetterberg H; Andreasson U; Höglund K; Irwin DJ; Grossman M; Weintraub D; Chen-Plotkin A; Wolk D; McCluskey L; Elman L; Shaw LM; Toledo JB; McBride J; Hernandez-Con P; Lee VM; Trojanowski JQ; Blennow K
    JAMA Neurol; 2019 Mar; 76(3):318-325. PubMed ID: 30508027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration.
    Scherling CS; Hall T; Berisha F; Klepac K; Karydas A; Coppola G; Kramer JH; Rabinovici G; Ahlijanian M; Miller BL; Seeley W; Grinberg LT; Rosen H; Meredith J; Boxer AL
    Ann Neurol; 2014 Jan; 75(1):116-26. PubMed ID: 24242746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum neurofilament light chain in progressive supranuclear palsy.
    Donker Kaat L; Meeter LH; Chiu WZ; Melhem S; Boon AJW; Blennow K; Zetterberg H; van Swieten JC
    Parkinsonism Relat Disord; 2018 Nov; 56():98-101. PubMed ID: 29937097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias.
    Baiardi S; Quadalti C; Mammana A; Dellavalle S; Zenesini C; Sambati L; Pantieri R; Polischi B; Romano L; Suffritti M; Bentivenga GM; Randi V; Stanzani-Maserati M; Capellari S; Parchi P
    Alzheimers Res Ther; 2022 Oct; 14(1):153. PubMed ID: 36221099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes.
    Magdalinou NK; Paterson RW; Schott JM; Fox NC; Mummery C; Blennow K; Bhatia K; Morris HR; Giunti P; Warner TT; de Silva R; Lees AJ; Zetterberg H
    J Neurol Neurosurg Psychiatry; 2015 Nov; 86(11):1240-7. PubMed ID: 25589779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Combination of Neurofilament Light, Glial Fibrillary Acidic Protein, and Neuronal Pentraxin-2 Discriminates Between Frontotemporal Dementia and Other Dementias.
    Bolsewig K; Hok-A-Hin YS; Sepe FN; Boonkamp L; Jacobs D; Bellomo G; Paoletti FP; Vanmechelen E; Teunissen CE; Parnetti L; Willemse EAJ
    J Alzheimers Dis; 2022; 90(1):363-380. PubMed ID: 36120776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of neurofilament light chain in frontotemporal dementia: a meta-analysis.
    Karantali E; Kazis D; Chatzikonstantinou S; Petridis F; Mavroudis I
    Aging Clin Exp Res; 2021 Apr; 33(4):869-881. PubMed ID: 32306372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal fluid neurofilament light chain protein levels in subtypes of frontotemporal dementia.
    Landqvist Waldö M; Frizell Santillo A; Passant U; Zetterberg H; Rosengren L; Nilsson C; Englund E
    BMC Neurol; 2013 May; 13():54. PubMed ID: 23718879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential levels of Neurofilament Light protein in cerebrospinal fluid in patients with a wide range of neurodegenerative disorders.
    Delaby C; Alcolea D; Carmona-Iragui M; Illán-Gala I; Morenas-Rodríguez E; Barroeta I; Altuna M; Estellés T; Santos-Santos M; Turon-Sans J; Muñoz L; Ribosa-Nogué R; Sala-Matavera I; Sánchez-Saudinos B; Subirana A; Videla L; Benejam B; Sirisi S; Lehmann S; Belbin O; Clarimon J; Blesa R; Pagonabarraga J; Rojas-Garcia R; Fortea J; Lleó A
    Sci Rep; 2020 Jun; 10(1):9161. PubMed ID: 32514050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic value of isolated plasma biomarkers and its combination in neurodegenerative dementias: A multicenter cohort study.
    Chen Y; Wang Y; Tao Q; Lu P; Meng F; Zhuang L; Qiao S; Zhang Y; Luo B; Liu Y; Peng G
    Clin Chim Acta; 2024 May; 558():118784. PubMed ID: 38588788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival in progressive supranuclear palsy and frontotemporal dementia.
    Chiu WZ; Kaat LD; Seelaar H; Rosso SM; Boon AJ; Kamphorst W; van Swieten JC
    J Neurol Neurosurg Psychiatry; 2010 Apr; 81(4):441-5. PubMed ID: 20360166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurofilament light chain level in cerebrospinal fluid can differentiate Parkinson's disease from atypical parkinsonism: Evidence from a meta-analysis.
    Sako W; Murakami N; Izumi Y; Kaji R
    J Neurol Sci; 2015 May; 352(1-2):84-7. PubMed ID: 25868897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal fluid neurofilament light concentration in motor neuron disease and frontotemporal dementia predicts survival.
    Skillbäck T; Mattsson N; Blennow K; Zetterberg H
    Amyotroph Lateral Scler Frontotemporal Degener; 2017 Aug; 18(5-6):397-403. PubMed ID: 28631955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The frontal assessment battery is not useful to discriminate progressive supranuclear palsy from frontotemporal dementias.
    Stamelou M; Diehl-Schmid J; Hapfelmeier A; Kontaxopoulou D; Stefanis L; Oertel WH; Bhatia KP; Papageorgiou SG; Höglinger GU
    Parkinsonism Relat Disord; 2015 Oct; 21(10):1264-8. PubMed ID: 26324212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP.
    Rojas JC; Bang J; Lobach IV; Tsai RM; Rabinovici GD; Miller BL; Boxer AL;
    Neurology; 2018 Jan; 90(4):e273-e281. PubMed ID: 29282336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum neurofilament light chain as a surrogate of cognitive decline in sporadic and familial frontotemporal dementia.
    Silva-Spínola A; Lima M; Leitão MJ; Durães J; Tábuas-Pereira M; Almeida MR; Santana I; Baldeiras I
    Eur J Neurol; 2022 Jan; 29(1):36-46. PubMed ID: 34375485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance of [
    Oliveira Hauer K; Pawlik D; Leuzy A; Janelidze S; Hall S; Hansson O; Smith R
    Parkinsonism Relat Disord; 2023 Jan; 106():105226. PubMed ID: 36442367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.